News Releases

Date	Title	Additional Formats
September 20, 2021	Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital
September 8, 2021	Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection
August 31, 2021	Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
August 10, 2021	Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones
August 5, 2021	Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.
August 2, 2021	Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI
May 25, 2021	Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 11, 2021	Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates
May 6, 2021	Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
April 29, 2021	Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints